TL;DR
A report from this year’s Clinical Trials on Alzheimer’s Disease conference highlighted two late-stage trials that did not significantly slow decline across all participants. Both produced findings in smaller groups, which need further testing. Separately, a 2026 review counted 158 drugs in Alzheimer’s clinical trials, with research increasingly targeting tau and inflammation alongside amyloid.
Two late-stage Alzheimer’s treatment trials discussed at this year’s Clinical Trials on Alzheimer’s Disease (CTAD) conference did not significantly slow decline across all participants, according to a report by Being Patient founder Deborah Kan. The findings underscore the gap between promising signals in smaller patient groups and evidence of benefit across a full trial, as the wider drug pipeline expands beyond amyloid-targeting treatments.
Give the gift of listening to someone you love
- Choose a 1-, 3-, 6- or 12-month membership
- They pick the audiobooks they love
- Easy to send by email
One trial tested AR1001, also known as mirodenafil, an oral drug developed by South Korean company AriBio. In the Phase 3 study, 1,535 people with mild cognitive impairment or early Alzheimer’s took a daily pill or placebo for one year. Being Patient reported that the drug did not change the rate of decline across the full group. Participants’ cGMP levels rose, indicating the drug affected its intended biological target, but that change did not establish a clinical benefit.
The other study tested Spectris, a headset made by Cognito Therapeutics that delivers flickering light and sound at 40 hertz for an hour each day. Among 673 people with mild to moderate Alzheimer’s, a year of use did not significantly slow decline compared with a sham device. The company reported a signal on three of five measures among participants with mild Alzheimer’s, a subgroup specified in advance. However, the analyses were not adjusted for multiple comparisons, which can increase the chance of a false-positive result. About 60 percent of participants completed the study.
Kan said she was not returning from the conference with a new therapy close to market on the basis of these results. Cognito said it planned to ask the U.S. Food and Drug Administration whether the Spectris findings could support an application for approval. The report does not say that the FDA has agreed to review an application or that either treatment is approved for Alzheimer’s.
Why Trial-Wide Results Matter
The findings matter because families and clinicians need evidence that a treatment helps the people it is intended for, not just a subset identified after results are examined. A signal in a subgroup can help researchers design another study, but it does not show that the effect is reliable or that the treatment should be used broadly. For Spectris, the completion rate and the statistical limits described in the report add questions that need to be addressed.
The results also illustrate why evidence of biological activity is not the same as evidence that patients decline more slowly. AR1001 raised cGMP levels, but the trial did not show an overall clinical effect. For people weighing trial participation or future treatment choices, the distinction between a measured change in the body and a meaningful difference in symptoms is important.
Products Worth Considering

Oura Ring 5 Smart Ring, Silver, Size 7

Withings Body Smart Accurate Scale for Body Weight, Fat Percentage and Body Composition

OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
As an affiliate, we earn on qualifying purchases.
A Broader Mix of Research Targets
The two trials represent only a small part of Alzheimer’s research. A 2026 report by Jeff Cummings, director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas, counted 158 drugs in 192 clinical trials. Of those medicines, 36 were in 54 Phase 3 trials. These figures describe the pipeline, not how many treatments will ultimately prove effective or reach patients.
According to the report, drugs targeting amyloid made up about one-third of the pipeline a decade ago and now account for roughly one-fifth. Drugs aimed at tau and inflammation each grew from about 6 percent to around 20 percent over that period. Cummings said, “Alzheimer’s is no longer an untreatable disease. It is now a disease with treatments that successfully interfere in the disease process.” That statement reflects his view of progress in treatments that affect disease processes; it does not mean the disease has been cured.
Kan also described combination treatment as a likely direction for research, including pairing approved anti-amyloid drugs with medicines aimed at other mechanisms. The report says some such trials are already underway, but it does not provide results showing whether combinations work better.
“Alzheimer’s is no longer an untreatable disease. It is now a disease with treatments that successfully interfere in the disease process.”
— Jeff Cummings, director of the Chambers-Grundy Center for Transformative Neuroscience at UNLV, as quoted in the Being Patient report
What the Subgroup Signals Establish
The available report does not establish whether the mild-Alzheimer’s subgroup finding for Spectris will hold up in another study. The lack of adjustment for multiple analyses and the fact that only about 60 percent of participants completed the trial leave questions about the strength and interpretation of the signal. Cognito’s planned discussion with the FDA is not a decision on approval.
For AR1001, the report gives the overall clinical result and the rise in cGMP, but does not provide detailed results for any smaller subgroup. It also does not describe all trial outcomes or provide enough information to determine whether a particular group might benefit. The report’s pipeline counts likewise do not predict which experimental drugs will succeed.
Upcoming Trials and FDA Discussions
Cognito said it will ask the FDA whether the Spectris data are sufficient to support filing for approval. The agency’s response, any submission, and the outcome of a review remain pending. A further trial could test whether the subgroup signal is repeatable and clarify how much daily device use is needed.
Kan highlighted a Lilly trial of donanemab in people whose blood tests indicate very early Alzheimer’s while their memory remains normal. Cummings said the study could help show whether treatment can prevent or delay symptoms in that population. The report also noted 83 late-stage Alzheimer’s trials recruiting participants in Being Patient’s latest Trials Update. Their results will add evidence over time, but no outcomes for those recruiting studies were provided.
Key Questions
Did either late-stage trial show an overall benefit?
No significant slowing of decline was reported across all participants in either study. The results described are not evidence that either treatment benefits the full trial population.
What did the Spectris study find in people with mild Alzheimer’s?
The report describes a signal of slower decline on three of five measures in that subgroup. Because multiple analyses were not adjusted for, and the finding has not been confirmed in another trial, it remains uncertain.
Is AR1001 approved to treat Alzheimer’s?
The source identifies mirodenafil, AR1001’s active ingredient, as approved in South Korea for erectile dysfunction. It does not report approval of AR1001 for Alzheimer’s.
How many Alzheimer’s drugs are in clinical trials?
A 2026 report by Jeff Cummings counted 158 drugs in 192 trials, including 36 drugs in 54 Phase 3 trials. The count does not indicate how many will be shown to work.
What major trial is being watched next?
Kan singled out Lilly’s donanemab trial in people with blood-test evidence of very early Alzheimer’s but normal memory. It is intended to examine whether treatment can prevent or delay symptoms; the report does not provide results.
Source: beingpatient.com
